Charles River Laboratories International (CRL) Current Deferred Revenue (2009 - 2025)

Charles River Laboratories International (CRL) has reported Current Deferred Revenue for 17 consecutive years, with $210.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Deferred Revenue fell 15.26% year-over-year to $210.4 million; the TTM figure through Dec 2025 stood at $210.4 million (down 15.26% YoY), while the FY2025 annual figure was $210.4 million, down 15.26% from the prior year.
• Current Deferred Revenue came in at $210.4 million for Q4 2025 at Charles River Laboratories International, down from $237.7 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $290.0 million in Q4 2022, with the low at $210.4 million in Q4 2025.
• Average Current Deferred Revenue over 5 years is $245.6 million, with a median of $249.4 million recorded in 2024.
• Across the five-year window, Current Deferred Revenue soared 35.75% in 2021 and fell 15.26% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $219.7 million in 2021, then surged by 32.0% to $290.0 million in 2022, then slipped by 5.86% to $273.0 million in 2023, then slipped by 9.04% to $248.3 million in 2024, then dropped by 15.26% to $210.4 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $210.4 million, $237.7 million, and $268.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.